Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia

This clinical trial is an open-label, multicenter, prospective phase 2 clinical trial targeting pediatric leukemia patients of infant age. The goal is to improve survival rates by varying the presence or absence of chemotherapy and hematopoietic stem cell transplantation based on genetic characteristics at the time of diagnosis and minimal residual disease (MRD) values measured by various methods after treatment. In addition, by clearly defining the patient group that requires hematopoietic stem cell transplantation, it is expected that the role of hematopoietic stem cell transplantation in i

Trial Details

NCT ID
NCT06516679
Phase
PHASE2
Sponsor
Yonsei University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Consolidation #4(without daunorubicin)
  • Consolidation #4(with daunorubicin)
  • Allogeneic hematopoietic stem cell transplantation after Consolidation #4(with daunorubicin)
Locations (sample)
  • Daegu, South Korea|35.87102,128.60121
  • Daejeon, South Korea|36.35022,127.3848
  • Hwasun, South Korea|35.06125,126.98746
  • Jeju City, South Korea|33.50972,126.52194
  • Pusan, South Korea|36.3809,128.3681

Key Eligibility Criteria

  • The age of diagnosis is less than 1 year old
  • The disgnosisi of ALL or ALAL(lymphoid predominant)
  • Informed consent of the parents(guardians) before participation in this study

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →